Reportable Segment Information (Tables)

9 Months Ended

Jun. 30, 2025

Summary of Financial Information for Each Reportable Segment

The following table presents various financial information for each reportable segment:


	Three months ended						Nine months ended
	June 30						June 30
(In millions - unaudited)	2025			2024			2025			2024
SALES
Life Sciences	$	162		$	195		$	468		$	617
Personal Care		147			175			426			473
Specialty Additives		131			150			380			429
Intermediates		33			36			104			108
Intersegment sales(a)		(10	)		(12	)		(31	)		(36	)
	$	463		$	544		$	1,347		$	1,591
OPERATING INCOME (LOSS)
Life Sciences(b)	$	(343	)	$	43		$	(301	)	$	125
Personal Care		25			31			64			59
Specialty Additives(c)		(345	)		10			(343	)		(40	)
Intermediates		4			6			6			22
Unallocated and other(d)		(49	)		(151	)		(262	)		(223	)
	$	(708	)	$	(61	)	$	(836	)	$	(57	)
DEPRECIATION EXPENSE
Life Sciences(e)	$	17		$	9		$	48		$	29
Personal Care(f)		7			10			23			27
Specialty Additives(g)		34			20			60			97
Intermediates		3			3			9			9
	$	61		$	42		$	140		$	162
AMORTIZATION EXPENSE
Life Sciences	$	5		$	6		$	13		$	18
Personal Care		8			10			26			32
Specialty Additives		2			3			7			8
Intermediates		—			—			1			1
	$	15		$	19		$	47		$	59
EBITDA(h)
Life Sciences	$	(321	)	$	58		$	(240	)	$	172
Personal Care		40			51			113			118
Specialty Additives		(309	)		33			(276	)		65
Intermediates		7			9			16			32
Unallocated and other		(49	)		(151	)		(262	)		(223	)
	$	(632	)	$	—		$	(649	)	$	164


	June 30		September 30
(In millions - unaudited)	2025		2024
TOTAL ASSETS
Life Sciences	$	1,531	$	1,778
Personal Care		699		950
Specialty Additives		1,048		1,516
Intermediates		118		127
Unallocated and other		1,225		1,274
	$	4,621	$	5,645

(a)

Intersegment sales from Intermediates are accounted for at prices that approximate fair value. All other intersegment sales are accounted for at cost.

(b)

Includes goodwill impairment of $375 million for Life Sciences for the three and nine months ended June 30, 2025.

(c)

Includes goodwill impairment of $331 million for Specialty Additives for the three and nine months ended June 30, 2025.

(d)

Includes a $8 million gain on sale and a $183 million impairment charge related to the sale of the Avoca business for the nine months ended June 30, 2025, and a $99 million impairment charge related to the sale of the Nutraceuticals business for the three and nine months ended June 30, 2024, within the loss on acquisitions and divestitures, net caption of the Statements of Condensed Consolidated Income (Loss).

(e)

Depreciation includes accelerated depreciation of $8 million and $21 million for Life Sciences for the three and nine months ended June 30, 2025, respectively.

(f)

Depreciation includes accelerated depreciation of $1 million for Personal Care for both the three and nine months ended June 30, 2024.

(g)

Depreciation includes accelerated depreciation of $19 million for Specialty Additives for both the three and nine months ended June 30, 2025, and $7 million and $55 million for the three and nine months ended June 30, 2024, respectively.

(h)

Excludes loss from discontinued operations, net of income taxes and other net periodic benefit loss. See the Statements of Condensed Consolidated Comprehensive Income (Loss) for applicable amounts excluded.

ASHLAND INC. 10-Q